Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study

Endocrinology, Diabetes & Metabolism
Santiago ToféVicente Pereg

Abstract

To evaluate in a real-world setting the effectiveness and tolerability of available GLP-1 RA drugs in patients with type 2 diabetes after a prolonged follow-up. Observational, retrospective, single-centre study in patients starting GLP-1 RA therapy. Change in HbA1c, fasting plasma glucose (FPG) and body mass index (BMI) along with gastrointestinal (GI) adverse events and withdrawal from GLP-1 RA therapy were evaluated. Lack of efficacy of GLP-1 RA therapy according to prespecified goals was also measured. A total of 735 patients were included, mean age 59.7 years, duration of diabetes 9.01 years, HbA1c 8.18% and BMI 38.56 kg/m2. Average follow-up was 18.97 months (range 4.2-39.09). All HbA1c (0.93%; P < 0.01), FPG (24 mg/dL; P < 0.01) and BMI (1.55 kg/m2; P < 0.05) were significantly reduced from baseline and maintained throughout follow-up, regardless of prescribed GLP-1 RA. GI adverse events were present in 13.81% of patients at first follow-up visit, 37.07% of patients discontinued GLP-1 RA treatment, and 38.63% did not meet efficacy goals. In a real-world setting, GLP-1 RA therapy is largely prescribed in severely obese patients with a long-standing and poorly controlled diabetes. All prescribed GLP-1 RAs significantly decr...Continue Reading

References

May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
Aug 19, 2009·Diabetologia·D Russell-JonesUNKNOWN Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group
Mar 11, 2010·Diabetes Care·John B BuseUNKNOWN DURATION-1 Study Group
May 23, 2012·Clinical Therapeutics·Vanita R ArodaByron J Hoogwerf
Dec 12, 2012·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Marc EvansLindsay George
Aug 31, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Luis-Emilio García-PérezDomingo Orozco-Beltrán
Apr 16, 2014·The Lancet. Diabetes & Endocrinology·Michaela DiamantMichael E Trautmann
Feb 14, 2015·Therapeutic Advances in Endocrinology and Metabolism·Jennifer M TrujilloSamuel L Ellis
Jun 10, 2015·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Pedro Mezquita-RayaMartin Lopez de la Torre Casares
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jun 28, 2016·Cell Metabolism·Daniel J Drucker
Aug 4, 2016·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·William B SaundersIftekhar Kalsekar
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Aug 13, 2017·Diabetes Care·Steven V Edelman, William H Polonsky
Sep 15, 2017·The New England Journal of Medicine·Rury R HolmanUNKNOWN EXSCEL Study Group
Dec 10, 2017·The Lancet. Diabetes & Endocrinology·M Angelyn BethelUNKNOWN EXSCEL Study Group
Jan 18, 2018·International Journal of Clinical Practice·Juan José Gorgojo-MartínezArturo Lisbona-Catalán

❮ Previous
Next ❯

Citations

Oct 28, 2019·Diabetes, Obesity & Metabolism·Louis S MatzaLuis-Emilio García-Pérez
Dec 10, 2020·Journal of Patient-reported Outcomes·Kristina S BoyeKarin S Coyne
Dec 11, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Yasushi IshigakiHiroshi Maegawa
Apr 17, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Kirsi NorrbackaIrene Romera
Jun 3, 2021·International Journal of Environmental Research and Public Health·Carlos MorillasJosé Luis Gorriz
Jul 27, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Kevin FernandoDipesh C Patel
Oct 30, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Rory J McCrimmonKaren Palmer
Nov 3, 2020·Clinical Diabetes : a Publication of the American Diabetes Association·Jaime P AlmandozCarlos Campos

❮ Previous
Next ❯

Software Mentioned

Statplus

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.